Landys Lopez Quezada, Felix Mba Medie, Rebeccah J. Luu, Robert B. Gaibler, Elizabeth P. Gabriel, Logan D. Rubio, Thomas J. Mulhern, Elizabeth E. Marr, Jeffrey T. Borenstein, Christine R. Fisher, Ashley L. Gard
{"title":"Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System (Adv. Biology 11/2024)","authors":"Landys Lopez Quezada, Felix Mba Medie, Rebeccah J. Luu, Robert B. Gaibler, Elizabeth P. Gabriel, Logan D. Rubio, Thomas J. Mulhern, Elizabeth E. Marr, Jeffrey T. Borenstein, Christine R. Fisher, Ashley L. Gard","doi":"10.1002/adbi.202470111","DOIUrl":null,"url":null,"abstract":"<p><b>SARS-CoV-2 Drug Efficacy</b></p><p>Rapid identification of effective therapeutics for emerging infectious diseases requires predictive preclinical drug screening tools that are operable at scale in high-containment laboratory environments. In article number 2300511 Ashley L. Gard, Christine R. Fisher, and co-workers at Draper used a high-throughput human airway microphysiological system, PREDICT96-ALI, to evaluate the efficacy of several SARS-CoV-2 interventions and distinguish ineffective lead compounds from clinically efficacious antivirals.\n\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":7234,"journal":{"name":"Advanced biology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adbi.202470111","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced biology","FirstCategoryId":"99","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adbi.202470111","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
Abstract
SARS-CoV-2 Drug Efficacy
Rapid identification of effective therapeutics for emerging infectious diseases requires predictive preclinical drug screening tools that are operable at scale in high-containment laboratory environments. In article number 2300511 Ashley L. Gard, Christine R. Fisher, and co-workers at Draper used a high-throughput human airway microphysiological system, PREDICT96-ALI, to evaluate the efficacy of several SARS-CoV-2 interventions and distinguish ineffective lead compounds from clinically efficacious antivirals.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
